Li Guang, Sehovic Admir, Xu Lee, Shukla Pawas, Zhang Lei, Zhou Ying, Wang Ping, Wu Abraham, Rimner Andreas, Zhang Pengpeng
Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
J Clin Med. 2022 Dec 13;11(24):7390. doi: 10.3390/jcm11247390.
As patient breathing irregularities can introduce a large uncertainty in targeting the internal tumor volume (ITV) of lung cancer patients, and thereby affect treatment quality, this study evaluates dose tolerance of tumor motion amplitude variations in ITV-based volumetric modulated arc therapy (VMAT). A motion-incorporated planning technique was employed to simulate treatment delivery of 10 lung cancer patients' clinical VMAT plans using original and three scaling-up (by 0.5, 1.0, and 2.0 cm) motion waveforms from single-breath four-dimensional computed tomography (4DCT) and multi-breath time-resolved 4D magnetic resonance imaging (TR-4DMRI). The planning tumor volume (PTV = ITV + 5 mm margin) dose coverage (PTV D95%) was evaluated. The repeated waveforms were used to move the isocenter in sync with the clinical leaf motion and gantry rotation. The continuous VMAT arcs were broken down into many static beam fields at the control points (2°-interval) and the composite plan represented the motion-incorporated VMAT plan. Eight motion-incorporated plans per patient were simulated and the plan with the native 4DCT waveform was used as a control. The first (D95% ≤ 95%) and second (D95% ≤ 90%) plan breaching points due to motion amplitude increase were identified and analyzed. The PTV D95% in the motion-incorporated plans was 99.4 ± 1.0% using 4DCT, closely agreeing with the corresponding ITV-based VMAT plan (PTV D95% = 100%). Tumor motion irregularities were observed in TR-4DMRI and triggered D95% ≤ 95% in one case. For small tumors, 4 mm extra motion triggered D95% ≤ 95%, and 6-8 mm triggered D95% ≤ 90%. For large tumors, 14 mm and 21 mm extra motions triggered the first and second breaching points, respectively. This study has demonstrated that PTV D95% breaching points may occur for small tumors during treatment delivery. Clinically, it is important to monitor and avoid systematic motion increase, including baseline drift, and large random motion spikes through threshold-based beam gating.
由于患者呼吸不规律会给肺癌患者内部肿瘤体积(ITV)的靶向带来很大不确定性,进而影响治疗质量,本研究评估了基于ITV的容积调强弧形放疗(VMAT)中肿瘤运动幅度变化的剂量耐受性。采用一种纳入运动的计划技术,使用来自单次呼吸四维计算机断层扫描(4DCT)和多呼吸时间分辨4D磁共振成像(TR-4DMRI)的原始运动波形以及三种放大(分别放大0.5、1.0和2.0 cm)的运动波形,模拟10例肺癌患者临床VMAT计划的治疗实施。评估计划靶体积(PTV = ITV + 5 mm边界)的剂量覆盖情况(PTV D95%)。使用重复的波形使等中心与临床叶片运动和机架旋转同步移动。连续的VMAT弧形在控制点(间隔2°)处分解为许多静态射野,合成计划代表纳入运动的VMAT计划。为每位患者模拟8个纳入运动的计划,并将使用原始4DCT波形的计划作为对照。确定并分析了由于运动幅度增加导致的第一个(D95%≤95%)和第二个(D95%≤90%)计划突破点。使用4DCT时,纳入运动的计划中PTV D95%为99.4±1.0%,与相应的基于ITV的VMAT计划(PTV D95% = 100%)非常接近。在TR-4DMRI中观察到肿瘤运动不规则,在1例中触发了D95%≤95%。对于小肿瘤,额外4 mm的运动触发D95%≤95%,6 - 8 mm的运动触发D95%≤90%。对于大肿瘤,额外14 mm和21 mm的运动分别触发了第一个和第二个突破点。本研究表明,在治疗实施过程中小肿瘤可能会出现PTV D95%突破点。临床上,监测并避免包括基线漂移在内的系统性运动增加以及通过基于阈值的射野门控避免大的随机运动尖峰非常重要。